Analytical Data
-
基因名
GAD
- Application
-
别名
GAD；Gamma-aminobutyric acid receptor subunit delta
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q97U27
-
表达区间
1-395aa
-
氨基酸序列
MRIREIEPIVLTSKEKGSATWASIMIVTRVITENGEVGYGEAVPTLRVISVYNAIKQVSKAYIGKEVEEVEKNYHEWYKQDFYLARSFESATAVSAIDIASWDIIGKELGAPIHKLLGGKTRDRVPVYANGWYQDCVTPEEFAEKAKDVVKMGYKALKFDPFGPYYDWIDERGLREAEERVKAVREAVGDNVDILIEHHGRFNANSAIMIAKRLEKYNPGFMEEPVHHEDVIGLRKYKASTHLRVALGERLISEKETAFYVEEGLVNILQPDLTNIGGVTVGRSVIKIAEANDVEVAFHNAFGSIQNAVEIQLSAVTQNLYLLENFYDWFPQWKRDLVYNETPVEGGHVKVPYKPGLGVSINEKIIEQLRAEPIPLDVIEEPVWVVKGTWKNYGV
-
分子量
44.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAD (Glutamic Acid Decarboxylase) is an essential enzyme that catalyzes the conversion of glutamate to gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system. Its critical role in neurotransmission highlights the significance of GAD in various neurological disorders, including epilepsy, anxiety, and Parkinson's disease. Research into GAD has spurred interest in its recombinant protein for both therapeutic and diagnostic applications. Recombinant GAD proteins can be produced in vitro using techniques such as recombinant DNA technology, which allows for high yields and purity. These proteins are valuable tools for studying the enzyme's kinetic properties and its interaction with GABA receptors. Furthermore, the use of recombinant GAD in immunotherapy shows promise in treating autoimmune conditions, such as Type 1 diabetes, where the body's immune system attacks insulin-producing cells. Investigating GAD's structure-function relationships through recombinant variants enhances our understanding of its enzymatic mechanisms and therapeutic potentials. As the demand for innovative treatments increases, the development of GAD recombinant protein continues to be a key area of research in neurobiology and immunotherapy, paving the way for novel approaches to manage related health conditions.
